Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments thereto, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences' board approved its Q3 FY26 (quarter ended 31 Dec 2025) unaudited financial results on 29 January 2026, with the statutory auditor (PSV Jain & Associates) issuing an unmodified limited review opinion. On a standalone basis, revenue from operations grew ~38% YoY to ₹957.37 lakhs in Q3, while profit after tax jumped to ₹94.74 lakhs (vs ₹28.49 lakhs in Q3 FY25). For the nine months, standalone revenue rose ~3% YoY to ₹2,622.33 lakhs and PAT nearly tripled to ₹245.72 lakhs. On a consolidated basis (which includes subsidiaries Eiko Scientific Solutions LLP and Eikovivify Logistics, and associate Reflux Pharmaceuticals), Q3 revenue grew ~60% YoY to ₹1,198.36 lakhs and 9M revenue grew ~30% to ₹3,436.68 lakhs, with consolidated 9M PAT at ₹382.75 lakhs. The company reports two segments: Speciality Chemicals & Pharma Intermediates and Logistics Services. No exceptional items were recorded in 9M FY26.
Strong YoY growth in both revenue and profitability, with a tripling of standalone PAT in Q3 and healthy 30%+ consolidated revenue growth for 9M FY26, which is likely to be viewed positively by shareholders.